Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals - NEC
- Sub-Industry: Health Care Equipment
- Symbol: NYSE:ABT
- CUSIP: 00282410
- Web: www.abbott.com
Capitalization:- Market Cap: $88.22123 billion
- Outstanding Shares: 1,735,272,000
Average Prices:- 50 Day Moving Avg: $48.18
- 200 Day Moving Avg: $44.68
- 52 Week Range: $37.38 - $51.13
P/E:- Trailing P/E Ratio: 57.12
- Foreward P/E Ratio: 18.22
- P/E Growth: 1.86
Sales & Book Value:- Annual Revenue: $22.3 billion
- Price / Sales: 3.96
- Book Value: $18.07 per share
- Price / Book: 2.81
Dividend:- Annual Dividend: $1.06
- Dividend Yield: 2.1%
Profitability:- EBIDTA: $4.77 billion
- Net Margins: 4.96%
- Return on Equity: 15.53%
- Return on Assets: 6.97%
Debt:- Debt-to-Equity Ratio: 0.75%
- Current Ratio: 2.91%
- Quick Ratio: 2.31%
Misc:- Average Volume: 6.35 million shs.
- Beta: 1.06
- Short Ratio: 2.82
Frequently Asked Questions for Abbott Laboratories (NYSE:ABT)
What is Abbott Laboratories' stock symbol?
Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."
How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?
Abbott Laboratories declared a quarterly dividend on Friday, June 9th. Shareholders of record on Friday, July 14th will be paid a dividend of $0.265 per share on Tuesday, August 15th. This represents a $1.06 annualized dividend and a yield of 2.08%. The ex-dividend date is Wednesday, July 12th. View Abbott Laboratories' Dividend History.
How were Abbott Laboratories' earnings last quarter?
Abbott Laboratories (NYSE:ABT) issued its earnings results on Thursday, July, 20th. The company reported $0.62 earnings per share for the quarter, topping analysts' consensus estimates of $0.60 by $0.02. The firm had revenue of $6.64 billion for the quarter, compared to analyst estimates of $6.63 billion. Abbott Laboratories had a return on equity of 15.53% and a net margin of 4.96%. Abbott Laboratories's revenue was up 24.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.55 EPS. View Abbott Laboratories' Earnings History.
When will Abbott Laboratories make its next earnings announcement?
What guidance has Abbott Laboratories issued on next quarter's earnings?
Abbott Laboratories updated its third quarter earnings guidance on Thursday, July, 20th. The company provided EPS guidance of $0.64-0.66 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.66. Abbott Laboratories also updated its FY17 guidance to $2.43-2.53 EPS.
Where is Abbott Laboratories' stock going? Where will Abbott Laboratories' stock price be in 2017?
14 brokerages have issued twelve-month price targets for Abbott Laboratories' shares. Their forecasts range from $42.00 to $58.00. On average, they expect Abbott Laboratories' stock price to reach $52.77 in the next twelve months. View Analyst Ratings for Abbott Laboratories.
What are analysts saying about Abbott Laboratories stock?
Here are some recent quotes from research analysts about Abbott Laboratories stock:
- 1. According to Zacks Investment Research, "For the majority of last one month, Abbott is trading above the broader Medical Products industry. We are optimistic about the company’s strong and consistent EPD and Medical Devices performance in the last reported first quarter. Overall, the company stands to benefit from the ongoing integration and synergy achievement of St. Jude. We are also looking forward to the company’s plans to focus on selling portfolio in core therapeutic areas. Recently, Abbott received CE mark for its TactiCath Sensor and Confirm Rx ICM products which is quite encouraging. The company also launched science-based nutrition drinks for better recovery from surgeries. On the flip side, Abbott’s sluggish pediatric business in China continues to hamper growth. Management is also concerned about the on-going economic problem in Venezuela that is expected to remain unresolved in the coming quarters." (6/21/2017)
- 2. Jefferies Group LLC analysts commented, "Investment summary: We are reiterating our Overweight rating for CORI and we are raising our PT by $2 to $12 following the positive donepezil patch bioequivalence results. Progress in the development of a proprietary pipeline is key, in our opinion, to the performance of the shares. Successful development of patch formulations of donepezil (Aricept) and/or memantine (Namenda) should position the company well to more-effectively monetize the transdermal drug delivery platform, in our opinion. Retention of meaningful commercialization rights could enable the company to turn the corner and pursue other opportunities more broadly, in our opinion. Corplex donepezil pilot study shows bioequivalence. Management reported that the Corplex donepezil pilot study met the FDA statistical criteria for bioequivalence. We note, too, that the patch was well-tolerated, with good skin and GI tolerability." (5/12/2017)
Who are some of Abbott Laboratories' key competitors?
Some companies that are related to Abbott Laboratories include Merck & Company (MRK), Sanofi (SNY), Novo Nordisk A/S (NVO), GlaxoSmithKline PLC (GSK), Eli Lilly and Company (LLY), Bristol-Myers Squibb Company (BMY), Astrazeneca PLC (AZN), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHPG), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY), Valeant Pharmaceuticals International (VRX), Patheon NV (PTHN), Taro Pharmaceutical Industries (TARO), Catalent (CTLT) and Akorn (AKRX).
Who are Abbott Laboratories' key executives?
Abbott Laboratories' management team includes the folowing people:
- Miles D. White, Chairman of the Board, Chief Executive Officer
- Brian B. Yoor, Chief Financial Officer, Senior Vice President - Finance
- Michael T. Rousseau, President - Cardiovascular and Neuromodulation
- Hubert L. Allen, Executive Vice President, General Counsel, Secretary
- Stephen R. Fussell, Executive Vice President - Human Resources
- Brian J. Blaser, Executive Vice President - Diagnostics Products
- John M. Capek Ph.D., Executive Vice President - Ventures
- Robert B. Ford, Executive Vice President - Medical Devices
- Heather L. Mason, Executive Vice President - Nutritional Products
- Roger Bird, Senior Vice President - U.S. Nutrition
Who owns Abbott Laboratories stock?
Abbott Laboratories' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Vontobel Asset Management Inc. (0.22%), US Bancorp DE (0.19%), Rockefeller Financial Services Inc. (0.15%), Jarislowsky Fraser Ltd (0.14%), NN Investment Partners Holdings N.V. (0.12%) and APG Asset Management N.V. (0.12%). Company insiders that own Abbott Laboratories stock include Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Warmuth, Miles D White, Robert B Ford, Robert E Funck, Roger Bird, Sally E Blount and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.
Who sold Abbott Laboratories stock? Who is selling Abbott Laboratories stock?
Abbott Laboratories' stock was sold by a variety of institutional investors in the last quarter, including DnB Asset Management AS, APG Asset Management N.V., Bank of Montreal Can, Vontobel Asset Management Inc., Hermes Investment Management Ltd., NN Investment Partners Holdings N.V., Rockefeller Financial Services Inc. and Exxonmobil Investment Management Inc. TX. Company insiders that have sold Abbott Laboratories stock in the last year include Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Jared Watkin, Joseph J Manning, Michael J Warmuth, Robert E Funck, Roger Bird and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.
Who bought Abbott Laboratories stock? Who is buying Abbott Laboratories stock?
Abbott Laboratories' stock was acquired by a variety of institutional investors in the last quarter, including Hexavest Inc., Fisher Asset Management LLC, Mn Services Vermogensbeheer B.V., National Pension Service, Pennsylvania Trust Co, Aperio Group LLC, Sit Investment Associates Inc. and Jarislowsky Fraser Ltd. Company insiders that have bought Abbott Laboratories stock in the last two years include Brian J Blaser, Miles D White, Robert B Ford and Sally E Blount. View Insider Buying and Selling for Abbott Laboratories.
How do I buy Abbott Laboratories stock?
Shares of Abbott Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Abbott Laboratories' stock price today?
One share of Abbott Laboratories stock can currently be purchased for approximately $50.84.
MarketBeat Community Rating for Abbott Laboratories (NYSE ABT)MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Abbott Laboratories (NYSE:ABT) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 3 Hold Ratings, 11 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.79) |
| Consensus Price Target: | $52.77 (3.79% upside) |
Analysts' Ratings History for Abbott Laboratories (NYSE:ABT)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/22/2017 | Barclays PLC | Reiterated Rating | Overweight | $52.00 -> $57.00 | Low |  |
| 7/21/2017 | Stifel Nicolaus | Reiterated Rating | Buy | $58.00 | Low | |
| 7/14/2017 | Cowen and Company | Reiterated Rating | Outperform | $48.00 -> $55.00 | Low | |
| 7/11/2017 | BMO Capital Markets | Reiterated Rating | Hold | $48.00 | Low | |
| 7/10/2017 | Morgan Stanley | Reiterated Rating | Equal Weight | | Low | |
| 6/30/2017 | Wells Fargo & Company | Reiterated Rating | Outperform | $47.50 -> $54.00 | Low | |
| 6/29/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $58.00 | Low | |
| 6/29/2017 | Guggenheim | Initiated Coverage | Buy | $58.00 | Low | |
| 6/21/2017 | BTIG Research | Initiated Coverage | Buy | $56.00 | Low | |
| 5/16/2017 | Goldman Sachs Group, Inc. (The) | Initiated Coverage | Neutral -> Neutral | $45.00 | Low | |
| 5/15/2017 | Royal Bank Of Canada | Reiterated Rating | Buy | | Low | |
| 9/19/2016 | Bank of America Corporation | Reiterated Rating | Buy | | N/A | |
| 8/9/2016 | Deutsche Bank AG | Reiterated Rating | Buy | | N/A | |
| 7/28/2016 | Argus | Reiterated Rating | Buy | $55.00 | N/A | |
| 6/21/2016 | Edward Jones | Upgrade | Hold -> Buy | | N/A | |
| 6/8/2016 | Credit Suisse Group | Reiterated Rating | Buy | | N/A | |
| 4/30/2016 | S&P Equity Research | Reiterated Rating | Hold | | N/A | |
| 4/30/2016 | Gabelli | Reiterated Rating | Buy | | N/A | |
| 4/28/2016 | Piper Jaffray Companies | Downgrade | Overweight -> Neutral | | N/A | |
| 4/14/2016 | First Global | Downgrade | Outperform -> Marketperform | | N/A | |
| 3/28/2016 | Leerink Swann | Boost Price Target | Market Perform | $37.00 -> $40.00 | N/A | |
| 1/29/2016 | Raymond James Financial, Inc. | Lower Price Target | Outperform | $46.00 -> $42.00 | N/A | |
| 1/29/2016 | William Blair | Downgrade | Outperform -> Market Perform | | N/A | |
(Data available from 7/24/2015 forward)
Earnings History for Abbott Laboratories (NYSE:ABT)Earnings History by Quarter for Abbott Laboratories (NYSE ABT)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/17/2017 | | $0.66 | | | | | N/A | |
| 7/20/2017 | Q2 2017 | $0.60 | $0.62 | $6.63 billion | $6.64 billion | View | N/A | |
| 4/19/2017 | 3/31/2017 | $0.43 | $0.48 | $6.16 billion | $6.34 billion | View | N/A | |
| 1/25/2017 | Q416 | $0.64 | $0.65 | $5.41 billion | $5.33 billion | View | Listen | |
| 10/19/2016 | Q316 | $0.58 | $0.59 | $5.29 billion | $5.30 billion | View | Listen | |
| 7/20/2016 | Q216 | $0.53 | $0.55 | $5.24 billion | $5.30 billion | View | Listen | |
| 4/20/2016 | Q116 | $0.39 | $0.41 | $4.77 billion | $4.90 billion | View | Listen | |
| 1/28/2016 | Q415 | $0.61 | $0.62 | $5.31 billion | $5.20 billion | View | Listen | |
| 10/21/2015 | Q315 | $0.53 | $0.54 | $5.16 billion | $5.15 billion | View | Listen | |
| 7/22/2015 | Q215 | $0.50 | $0.52 | $5.15 billion | $5.20 billion | View | Listen | |
| 4/22/2015 | Q115 | $0.42 | $0.47 | $4.85 billion | $4.90 billion | View | Listen | |
| 1/29/2015 | Q414 | $0.68 | $0.71 | $5.48 billion | $5.36 billion | View | Listen | |
| 10/22/2014 | Q314 | $0.60 | $0.62 | $5.62 billion | $5.10 billion | View | Listen | |
| 7/16/2014 | Q214 | $0.51 | $0.54 | $5.53 billion | $5.55 billion | View | Listen | |
| 4/16/2014 | Q114 | $0.36 | $0.41 | $5.29 billion | $5.24 billion | View | Listen | |
| 1/22/2014 | Q413 | $0.58 | $0.58 | $5.72 billion | $5.66 billion | View | Listen | |
| 10/16/2013 | Q313 | $0.52 | $0.55 | $5.46 billion | $5.37 billion | View | Listen | |
| 7/17/2013 | Q2 2013 | $0.44 | $0.46 | $5.53 billion | $5.45 billion | View | Listen | |
| 4/17/2013 | Q1 2013 | $0.41 | $0.42 | $5.42 billion | $5.38 billion | View | Listen | |
| 1/23/2013 | Q4 2012 | $1.50 | $1.51 | $10.58 billion | $10.80 billion | View | Listen | |
| 10/17/2012 | | $1.28 | $1.30 | | | View | N/A | |
| 7/18/2012 | | $1.22 | $1.23 | | | View | N/A | |
| 4/18/2012 | | $1.00 | $1.03 | | | View | N/A | |
| 1/25/2012 | | $1.44 | $1.45 | | | View | N/A | |
| 10/19/2011 | | $1.17 | $1.18 | | | View | N/A | |
| 7/20/2011 | | $1.12 | $1.12 | | | View | N/A | |
| 4/20/2011 | | $0.90 | $0.91 | | | View | N/A | |
| 1/26/2011 | | $1.29 | $1.30 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Abbott Laboratories (NYSE:ABT)2017 EPS Consensus Estimate: $2.44
2018 EPS Consensus Estimate: $2.83
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | $0.43 | $0.50 | $0.45 |
| Q2 2017 | 3 | $0.59 | $0.61 | $0.60 |
| Q3 2017 | 3 | $0.64 | $0.68 | $0.66 |
| Q4 2017 | 3 | $0.72 | $0.73 | $0.73 |
| Q1 2018 | 2 | $0.55 | $0.56 | $0.56 |
| Q2 2018 | 2 | $0.69 | $0.71 | $0.70 |
| Q3 2018 | 2 | $0.74 | $0.76 | $0.75 |
| Q4 2018 | 2 | $0.80 | $0.84 | $0.82 |
(Data provided by Zacks Investment Research)
Current Dividend Information for Abbott Laboratories (NYSE:ABT)| Next Dividend: | 8/15/2017 |
| Annual Dividend: | $1.06 |
| Dividend Yield: | 2.08% |
| Dividend Growth: | 22.90% (3 Year Average) |
| Payout Ratio: | 149.30% (Trailing 12 Months of Earnings)
42.74% (Based on This Year's Estimates)
37.99% (Based on Next Year's Estimates)
|
| Track Record: | 44 Years of Consecutive Dividend Growth |
Dividend History by Quarter for Abbott Laboratories (NYSE ABT)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 6/9/2017 | quarterly | $0.27 | 2.25% | 7/12/2017 | 7/14/2017 | 8/15/2017 |
| 2/17/2017 | quarterly | $0.27 | 2.36% | 4/11/2017 | 4/14/2017 | 5/15/2017 |
| 12/9/2016 | quarterly | $0.27 | 2.7% | 1/11/2017 | 1/13/2017 | 2/15/2017 |
| 9/15/2016 | quarterly | $0.26 | 2.48% | 10/12/2016 | 10/14/2016 | 11/15/2016 |
| 6/10/2016 | quarterly | $0.26 | 2.75% | 7/13/2016 | 7/15/2016 | 8/15/2016 |
| 2/19/2016 | quarterly | $0.26 | 2.66% | 4/13/2016 | 4/15/2016 | 5/16/2016 |
| 12/11/2015 | quarterly | $0.26 | 2.32% | 1/13/2016 | 1/15/2016 | 2/16/2016 |
| 9/17/2015 | quarterly | $0.24 | 2.22% | 10/13/2015 | 10/15/2015 | 11/15/2015 |
| 6/12/2015 | quarterly | $0.24 | 2% | 7/13/2015 | 7/15/2015 | 8/15/2015 |
| 2/20/2015 | quarterly | $0.24 | 2.03% | 4/13/2015 | 4/15/2015 | 5/15/2015 |
| 12/12/2014 | quarterly | $0.24 | 2.21% | 1/13/2015 | 1/15/2015 | 2/13/2015 |
| 9/11/2014 | quarterly | $0.22 | 2.07% | 10/10/2014 | 10/15/2014 | 11/15/2014 |
| 6/13/2014 | quarterly | $0.22 | 2.21% | 7/11/2014 | 7/15/2014 | 8/15/2014 |
| 2/21/2014 | quarterly | $0.22 | 2.26% | 4/11/2014 | 4/15/2014 | 5/15/2014 |
| 10/16/2013 | quarterly | $0.22 | 2.37% | 1/13/2014 | 1/15/2014 | 2/15/2014 |
| 9/12/2013 | quarterly | $0.14 | 1.61% | 10/10/2013 | 10/15/2013 | 11/15/2013 |
| 6/14/2013 | quarterly | $0.14 | 1.52% | 7/11/2013 | 7/15/2013 | 8/15/2013 |
| 2/15/2013 | quarterly | $0.14 | 1.61% | 4/11/2013 | 4/15/2013 | 5/15/2013 |
| 12/14/2012 | quarterly | $0.14 | 0.86% | 1/11/2013 | 1/15/2013 | 2/15/2013 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for Abbott Laboratories (NYSE:ABT)Insider Ownership Percentage: 0.76%
Institutional Ownership Percentage: 71.08%
Insider Trades by Quarter for Abbott Laboratories (NYSE:ABT)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/15/2017 | Jared Watkin | Insider | Sell | 552 | $47.97 | $26,479.44 | |
| 6/8/2017 | Stephen R Fussell | Insider | Sell | 196,550 | $46.00 | $9,041,300.00 | |
| 4/27/2017 | Roger Bird | Insider | Sell | 5,600 | $43.82 | $245,392.00 | |
| 4/26/2017 | Joseph J Manning | Insider | Sell | 4,200 | $43.95 | $184,590.00 | |
| 3/1/2017 | Michael J. Warmuth | Insider | Sell | 3,851 | $45.39 | $174,796.89 | |
| 2/23/2017 | Robert E Funck | VP | Sell | 25,500 | $45.50 | $1,160,250.00 | |
| 2/22/2017 | Roger Bird | Insider | Sell | 13,222 | $45.02 | $595,254.44 | |
| 2/21/2017 | Deepak S Nath | Insider | Sell | 319 | $44.98 | $14,348.62 | |
| 1/31/2017 | Heather L Mason | Insider | Sell | 35,700 | $40.77 | $1,455,489.00 | |
| 12/20/2016 | Brian J Blaser | Insider | Buy | 15,580 | $38.45 | $599,051.00 | |
| 12/14/2016 | Robert B Ford | Insider | Buy | 12,775 | $39.09 | $499,374.75 | |
| 11/10/2016 | Miles D White | Chairman | Buy | 121,456 | $40.45 | $4,912,895.20 | |
| 11/1/2016 | Sally E Blount | Director | Buy | 5,100 | $39.24 | $200,124.00 | |
| 9/26/2016 | Daniel Gesua Sive Salvadori | SVP | Sell | 815 | $41.71 | $33,993.65 | |
| 7/28/2016 | Stephen R Fussell | Insider | Sell | 41,500 | $45.00 | $1,867,500.00 | |
| 7/26/2016 | Michael J Warmuth | Insider | Sell | 26,800 | $43.49 | $1,165,532.00 | |
| 7/25/2016 | Miles D White | Chairman | Buy | 242,547 | $43.18 | $10,473,179.46 | |
| 7/25/2016 | Robert E Funck | VP | Sell | 26,800 | $43.08 | $1,154,544.00 | |
| 6/28/2016 | Hubert L Allen | EVP | Sell | 3,400 | $37.14 | $126,276.00 | |
| 6/15/2016 | Jared Watkin | SVP | Sell | 552 | $37.63 | $20,771.76 | |
| 6/1/2016 | Brian B Yoor | CFO | Sell | 565 | $39.49 | $22,311.85 | |
| 4/28/2016 | Deepak S Nath | SVP | Sell | 53 | $41.31 | $2,189.43 | |
| 3/31/2016 | Jaime Contreras | SVP | Sell | 462 | $41.78 | $19,302.36 | |
| 2/29/2016 | Brian B Yoor | CFO | Sell | 865 | $39.12 | $33,838.80 | |
| 2/29/2016 | Deepak S Nath | SVP | Sell | 793 | $39.27 | $31,141.11 | |
| 2/29/2016 | Robert B Ford | EVP | Sell | 1,706 | $39.28 | $67,011.68 | |
| 2/29/2016 | Robert E Funck | VP | Sell | 1,333 | $39.30 | $52,386.90 | |
| 2/22/2016 | Jared Watkin | SVP | Sell | 554 | $39.09 | $21,655.86 | |
| 2/16/2016 | Deepak S. Nath | SVP | Sell | 171 | $37.13 | $6,349.23 | |
| 12/16/2015 | Miles D. White | CEO | Sell | 438,000 | $46.00 | $20,148,000.00 | |
| 8/18/2015 | Stephen R. Fussell | EVP | Sell | 13,096 | $50.46 | $660,824.16 | |
| 4/27/2015 | Heather L Mason | EVP | Sell | 13,500 | $47.45 | $640,575.00 | |
| 4/27/2015 | Roger Bird | SVP | Sell | 28,548 | $47.57 | $1,358,028.36 | |
| 3/26/2015 | J. Scott White | SVP | Sell | 12,483 | $46.68 | $582,706.44 | |
| 3/2/2015 | Jaime Contreras | SVP | Sell | 9,209 | $47.34 | $435,954.06 | |
| 2/4/2015 | John M Capek | EVP | Sell | 34,292 | $45.66 | $1,565,772.72 | |
| 11/25/2014 | Jaime Contreras | SVP | Sell | 51,600 | $44.07 | $2,274,012.00 | |
| 10/29/2014 | Miles D White | CEO | Sell | 440,800 | $42.52 | $18,742,816.00 | |
| 3/3/2014 | John Landgraf | EVP | Sell | 17,293 | $39.38 | $680,998.34 | |
| 3/3/2014 | Katherine Doyle | SVP | Sell | 6,639 | $39.01 | $258,987.39 | |
| 3/3/2014 | Robert Funck | VP | Sell | 1,413 | $38.97 | $55,064.61 | |
| 2/18/2014 | John Landgraf | EVP | Sell | 1,583 | $39.10 | $61,895.30 | |
| 1/29/2014 | Michael Warmuth | EVP | Sell | 11,430 | $36.21 | $413,880.30 | |
| 12/6/2013 | Jean-Yves Pavee | SVP | Sell | 5,855 | $37.46 | $219,328.30 | |
| 11/7/2013 | Stephen Fussell | EVP | Sell | 10,466 | $37.59 | $393,416.94 | |
| 10/30/2013 | Jaime Contreras | SVP | Sell | 25,368 | $36.85 | $934,810.80 | |
| 6/7/2013 | Heather L Mason | SVP | Sell | 12,000 | $37.01 | $444,120.00 | |
| 2/1/2013 | William A Osborn | Director | Buy | 10,000 | $33.86 | $338,600.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Abbott Laboratories (NYSE:ABT)
Latest Headlines for Abbott Laboratories (NYSE:ABT)
| Source: |
|
| Date | Headline |
|---|
 | Abbott Laboratories Expected to Post FY2017 Earnings of $2.50 Per Share (NYSE:ABT)
www.americanbankingnews.com - July 24 at 8:49 AM |
| FY2017 Earnings Estimate for Abbott Laboratories (ABT) Issued By William Blair
www.americanbankingnews.com - July 24 at 8:49 AM |
| Jefferies Group Comments on Abbott Laboratories' Q3 2017 Earnings (ABT)
www.americanbankingnews.com - July 24 at 7:50 AM |
| Abbott Laboratories (NYSE:ABT) Expected to Post Quarterly Sales of $6.66 Billion
www.americanbankingnews.com - July 23 at 12:15 PM |
| Abbott Laboratories' (ABT) Overweight Rating Reaffirmed at Barclays PLC
www.americanbankingnews.com - July 22 at 8:53 PM |
 | Abbott Labs (ABT) PT Raised to $62 at Argus on 2Q Beat & FY17 Raise; 'Positive View of Growth Prospects' - StreetInsider.com
www.streetinsider.com - July 21 at 9:40 PM |
| Abbott Labs (ABT) PT Raised to $57 at Barclays on 2Q Beat & FY17 EPS Raise; '2H Outlook Appears Bright' - StreetInsider.com
www.streetinsider.com - July 21 at 9:40 PM |
| Abbott Laboratories' (ABT) "Buy" Rating Reaffirmed at Stifel Nicolaus
www.americanbankingnews.com - July 21 at 5:29 PM |
 | Today's Research Reports on Stocks to Watch: Abbott Laboratories and Pfizer Inc.
finance.yahoo.com - July 21 at 4:38 PM |
| Company News for July 21, 2017
finance.yahoo.com - July 21 at 4:38 PM |
| Behind the Major Drivers of JNJ’s Medical Device Growth
finance.yahoo.com - July 21 at 4:38 PM |
| Abbott Laboratories (NYSE:ABT) Price Target Raised to $6.00 at Argus
www.americanbankingnews.com - July 21 at 1:45 PM |
| Deutsche Bank AG Increases Abbott Laboratories (ABT) Price Target to $5.00
www.americanbankingnews.com - July 21 at 1:44 PM |
| Zacks: Brokerages Anticipate Abbott Laboratories (NYSE:ABT) to Announce $0.66 EPS
www.americanbankingnews.com - July 21 at 9:54 AM |
 | Abbott Q2 Profit Falls, But Results Top View; Lifts 2017 Profit Outlook
www.rttnews.com - July 21 at 1:34 AM |
| LabCorp (LH) Q2 Earnings: Is Disappointment in the Cards?
finance.yahoo.com - July 20 at 8:30 PM |
| Abbott Laboratories (ABT) Releases Q3 Earnings Guidance
www.americanbankingnews.com - July 20 at 5:38 PM |
 | Abbott Labs (ABT) Beats on Q2 Earnings and Sales, View Up - Nasdaq
www.nasdaq.com - July 20 at 3:28 PM |
| Abbott (ABT) Tops Earnings Estimates in Q2, Misses on Sales
finance.yahoo.com - July 20 at 3:28 PM |
| US STOCKS-Wall St flat as earnings from some big names disappoint
finance.yahoo.com - July 20 at 3:28 PM |
| Abbott Zeros In On A 2-Year High After Topping Q2 Sales, Profits
finance.yahoo.com - July 20 at 3:28 PM |
| US STOCKS-Wall St flat as consumer stocks, weak earnings weigh
finance.yahoo.com - July 20 at 3:28 PM |
| Abbott CEO: Another Alere-Related Divestiture Coming Soon
finance.yahoo.com - July 20 at 3:28 PM |
| Abbott Labs (ABT) Beats on Q2 Earnings and Sales, View Up
finance.yahoo.com - July 20 at 3:28 PM |
| Abbott profit forecast gets a lift from St. Jude integration
finance.yahoo.com - July 20 at 3:28 PM |
| Abbott tops Street 2Q forecasts
finance.yahoo.com - July 20 at 3:28 PM |
| US STOCKS-S&P, Dow flat as retailers weigh; Nasdaq edges higher
finance.yahoo.com - July 20 at 3:28 PM |
| Abbott Laboratories (ABT) Releases Earnings Results
www.americanbankingnews.com - July 20 at 9:53 AM |
| Abbott Laboratories (ABT) Releases FY17 Earnings Guidance
www.americanbankingnews.com - July 20 at 9:42 AM |
| What To Watch For In Abbott's Q2 Earnings - Nasdaq
www.nasdaq.com - July 19 at 3:36 PM |
| Medical Product Stocks' Earnings on Jul 20: ABT, ISRG & More - Nasdaq
www.nasdaq.com - July 19 at 3:36 PM |
 | Abbott Laboratories (NYSE:ABT), American Express Company ... - Benzinga
www.benzinga.com - July 19 at 3:36 PM |
 | Quidel Diversifies With Alere's Triage Assets - TheStreet.com
www.thestreet.com - July 18 at 8:39 PM |
| Quidel Diversifies With Alere's Triage Assets
finance.yahoo.com - July 18 at 8:39 PM |
 | Risk Arbitrage Today: 2 M&A Deals That Had Price Cuts With A Little Meat Left On The Bone
seekingalpha.com - July 18 at 3:36 PM |
| Abbott's Tarnished Deal Sparkles for Another
finance.yahoo.com - July 18 at 3:35 PM |
| Can Abbott Laboratories (ABT) Pull a Surprise in Q2 Earnings? - Nasdaq
www.nasdaq.com - July 18 at 1:43 AM |
| Can Abbott Laboratories (ABT) Pull a Surprise in Q2 Earnings?
finance.yahoo.com - July 17 at 8:40 PM |
| Earnings Roundup: JNJ, IBM, And LMT Report Q2 Results Tomorrow - Benzinga
www.benzinga.com - July 17 at 3:37 PM |
| Science: Sugar substitute effects not so sweet
finance.yahoo.com - July 17 at 3:37 PM |
| Corporate America Is About to Unleash Great Earnings Reports, Hopefully: Week Ahead - TheStreet.com
www.thestreet.com - July 16 at 8:32 AM |
| Abbott Labs (ABT) PT Raised to $55 at Cowen; 'Refining Sales ... - StreetInsider.com
www.streetinsider.com - July 14 at 10:15 PM |
| ABT: Wall Street Analysts’ Recommendations ahead of Q2 Earnings
finance.yahoo.com - July 14 at 5:10 PM |
| Will Abbott Laboratories Beat Analyst Revenue Estimates in Q2?
finance.yahoo.com - July 14 at 5:10 PM |
| What to Expect from Abbott Laboratories’ 2Q17 Earnings
finance.yahoo.com - July 14 at 5:10 PM |
| Cowen and Company Reiterates "Outperform" Rating for Abbott Laboratories (ABT)
www.americanbankingnews.com - July 14 at 1:25 PM |
| Traders Buy Large Volume of Abbott Laboratories Call Options (NYSE:ABT)
www.americanbankingnews.com - July 14 at 7:34 AM |
| Abbott teams up with Bigfoot Bio in diabetes management - Seeking Alpha
seekingalpha.com - July 14 at 1:52 AM |
| Abbott, Novartis Show Promise Amid Healthcare Decline, Tiffany Lands Much Needed Boost -ICYMI Thurs. - TheStreet.com
www.thestreet.com - July 14 at 1:52 AM |
| Abbott Laboratories (ABT) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - July 13 at 9:20 PM |
Abbott Laboratories (ABT) Chart for Monday, July, 24, 2017
